CARB-X

Join CARB-X Alliance Director Vega Masignani, PhD, at Vaccine Innovation Forum World 2026 in Shanghai, China, for her presentation, “Introduction into CARB-X working model and upcoming funding rounds.” #IDSky 🧪

📆 Friday, March 13
⏰ 9:40 – 10 AM CST
🔗 Register here: bit.ly/3PayamO

Boston University
@asprgov.bsky.social
@niaidnews.bsky.social
Wellcome Trust
@gatesfoundation.bsky.social
@dzif.bsky.social

CARB-X is awarding US$1.2M to the Andrew G. Myers Research Group to develop enhanced antibiotics that target multi-drug-resistant Gram-negative bacterial pathogens to treat urinary tract infections, pneumonia, and bloodstream infections. #IDSky 🧪

🔗 Read here: bit.ly/4bcWvkw

📘 New publication!
CARB-X product developer @sniprbiome.com published the results from its first-in-human Phase 1a trial of SNIPR001. CARB-X supported the preclinical development of SNIPR001 and is also a co-funder of its Phase 1a and Phase 1b clinical trials. #IDSky 🧪
🔗 Read here: bit.ly/4cWNptp

This publication marks the next step in CARB-X’s Portfolio Acceleration Tool intended to support the development of new decolonization agents. Colonization by drug-resistant pathogens is linked to serious infections in compromised patients.

📘 New publication supported by CARB-X!

“Current infection control practices for multidrug-resistant organisms (MDRO): a survey of the Society for Healthcare Epidemiology of America (SHEA) research network and affiliated US-based hospitals” #IDSky 🧪

🔗 Read here: bit.ly/474t3e0

Early registration for #GAMRIC2026 is open now through July 15! Join us in Lisbon, Portugal from Sept. 22 – 24, 2026. Don’t wait to register – last year’s event attracted extraordinary demand and sold out in advance. #IDSky 🧪
🔗 Register here: bit.ly/4kE2oKV

@bulaw.bsky.social
Boston University
@asprgov.bsky.social
@niaidnews.bsky.social
Wellcome Trust
@gatesfoundation.bsky.social
@dzif.bsky.social

📢 NEW CARB-X funding round!
Featuring four distinct product themes for #therapeutics, #preventatives, and #diagnostics. EOIs may be submitted from 8 April 2026 at 10:00 ET – 22 April 2026 at 23:59 ET. #IDSky #ChemSky 🧪
🔗 Full announcement: bit.ly/4s1dtYX
🔗 TPPs and entry criteria: bit.ly/4dTKvDj

Join CARB-X at the 10th AMR Conference in Basel, Switzerland! Kevin Outterson, Richard Alm, and Betsy Wonderly Trainor are speaking at various sessions. #IDSky 🧪

🔗 Register here: bit.ly/3MAkyQU

Join CARB-X interim Chief of Research and Development Richard Alm for his keynote speech about how CARB-X accelerates novel antibacterial products toward clinical development at the @ausantibiotics.bsky.social Annual Scientific Meeting. #IDSky 🧪
📆 Feb. 27
⏰ 3:45 – 4:15 PM ACDT
🔗 bit.ly/3MMmdTE

📢 GAMRIC 2026 registration opening soon!

Mark your calendar for March 1 and be one of the first to register for the 2nd Global AMR Innovators Conference. Don’t wait to register – the inaugural GAMRIC attracted extraordinary demand and sold out in advance. #IDSky 🧪

🔗 bit.ly/4kE2oKV

📢 CARB-X 2026 funding round news!
CARB-X is pleased to share we will be accepting applications for therapeutic, preventative, and diagnostic products as part of our 2026 Funding Round. Full details will be published soon. #IDSky 🧪
📩 Sign up for the CARB-X newsletter to receive updates: bit.ly/42hkl

Attending the AMR 2026 Summit in Sydney, Australia? CARB-X interim Chief of Research and Development Richard Alm and CARB-X Director of External Affairs Louise Norton-Smith are speaking at multiple sessions. #AMR #IDSky 🧪

💼 CARB-X is hiring an ALLIANCE DIRECTOR!

We are seeking an expert in therapeutic product research and development who will provide scientific leadership and direct the project management activities for the diverse CARB-X therapeutic portfolio. #IDSky 🧪

➡️ Apply today! bit.ly/3YLyo5V

💼 CARB-X is hiring a CHIEF OF R&D!

This role leads the team that identifies and translates strategic priorities into public funding calls and contributes to pre-award review and investment decisions, as well as post-award support and portfolio transitions. #IDSky 🧪

➡️ Apply today! bit.ly/3YLyo5V

Boston University
@bulaw.bsky.social
@asprgov.bsky.social
@niaidnews.bsky.social
Wellcome Trust
@gatesfoundation.bsky.social
@dzif.bsky.social

CARB-X is awarding US$1.8 million to Chembio Diagnostic Systems, Inc. to develop a rapid point-of-care test for the detection of Immunoglobulin A (IgA) antibodies to diagnose acute infection of Salmonella enterica serovar Typhi. #IDSky 🧪

🔗 Read here: bit.ly/4k5Aqau

CARB-X is committed to driving innovation in antibacterial R&D, supporting a diverse portfolio of diagnostics & nontraditional therapeutics to address dangerous infections. We look forward to continued collaboration with the AMR ecosystem to bring bold science to the clinic.

Antibiotic resistance could undo a century of medical progress – but four advances are changing the story Antibiotics transformed health care for the better, but their diminishing effectiveness may soon be its undoing. Researchers are studying ways to fight back against resistance.

AMR is an urgent, growing threat. André O. Hudson, PhD writes about four major trends driving solutions to address the AMR crisis for The Conversation U.S. #IDSky 🧪

🔗 Read here:

💼 CARB-X is hiring an ALLIANCE DIRECTOR!

We are seeking an expert in therapeutic product research and development who will provide scientific leadership and direct the project management activities for the diverse CARB-X therapeutic portfolio. #IDSky 🧪

➡️ Apply today! bit.ly/3YLyo5V

CARB-X is pleased to co-sponsor the AMR Science-Policy Forum at @escmid.bsky.social Global 2026. The forum will bridge the gap between research insights and effective policy action. Register now to take advantage of discounted early registration, which ends February 11. #IDSky 🧪

🔗 bit.ly/46pStCw

Visit CARB-X’s virtual booth at ACC 2026 from Feb. 4-5 to learn more about our work! This free, virtual event is RCPath CPD approved for 8 credits. Earn continuing education credits and learn about antimicrobial drug discovery and clinical trial networks. #IDSky 🧪

🔗 Register: bit.ly/4t29ooI

💼 CARB-X is hiring another SENIOR FINANCE AND RESEARCH ADMINISTRATOR!

We are looking for a collaborative, organized individual who will manage a portfolio of product developers who are awarded funding from CARB-X.

➡️ Apply today! bit.ly/3YLyo5V

Boston University
@bulaw.bsky.social
@asprgov.bsky.social
@niaidnews.bsky.social
Wellcome Trust
@gatesfoundation.bsky.social
@dzif.bsky.social

CARB-X announced today its renewed partnership with Wellcome Trust, a global charitable foundation which co-founded CARB-X in 2016. Wellcome will provide new funding of up to US$60 million to support early-stage R&D of innovative antibacterial products. #IDSky 🧪
🔗 bit.ly/49OLSCC

Join CARB-X Executive Director Kevin Outterson J.D., LL.M., ESQ, and CARB-X Senior Alliance Manager Su Chiang, PhD, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)! #IDSky 🧪

🔗 Register here: bit.ly/49KL5Tg

💼 CARB-X is hiring another SENIOR FINANCE AND RESEARCH ADMINISTRATOR!

We are looking for a collaborative, organized individual who will manage a portfolio of product developers who are awarded funding from CARB-X.

➡️ Apply today! bit.ly/3YLyo5V

A recent publication in The Lancet Microbe examined global public and philanthropic investments in antibacterial R&D between 2017 and 2023, emphasizing the critical role of public-private partnerships like CARB-X. #IDSky 🧪

🔗 Read here: bit.ly/3NdH16x

Clarametyx Biosciences shared positive topline data from its Phase 2a study evaluating CMTX-101 in cystic fibrosis. CARB-X supported CMTX-101 from Lead Optimization through preclinical, with the project graduating from the CARB-X portfolio in 2022. #IDSky 🧪

🔗 Read here: bit.ly/4qm2yZk